Trial Profile
Phase II/III trial of patients with Pompe disease previously treated with alglucosidase alfa who were then switched to treatment with reveglucosidase alfa
Status:
Recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 01 Mar 2016
Price :
$35
*
At a glance
- Drugs Reveglucosidase alfa (Primary)
- Indications Glycogen storage disease type II
- Focus Therapeutic Use
- 01 Mar 2016 New trial record
- 25 Feb 2016 According to BioMarin Pharmaceutical media release, the company shared interim results.